Aerosolized Amikacin as Adjunctive Therapy of Ventilator-associated Pneumonia Caused by Multidrug-resistant Gram-negative Bacteria: A Single-center Randomized Controlled Trial
Background: Aerosolized amikacin (AA) is a current option for the management of ventilator-associated pneumonia (VAP) caused by multidrug-resistant Gram-negative bacteria (MDR-GNB), as it is reported that AA could increase the alveolar level of the drug without increasing systemic toxicity. This stu...
Main Authors: | Chang Liu, Yu-Ting Zhang, Zhi-Yong Peng, Qing Zhou, Bo Hu, Hui Zhou, Jian-Guo Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2017-01-01
|
Series: | Chinese Medical Journal |
Subjects: | |
Online Access: | http://www.cmj.org/article.asp?issn=0366-6999;year=2017;volume=130;issue=10;spage=1196;epage=1201;aulast=Liu |
Similar Items
-
Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
by: Antoni Torres, et al.
Published: (2018-12-01) -
Effect of extended infusion of meropenem and nebulized amikacin on Gram-negative multidrug-resistant ventilator-associated pneumonia
by: Mona Ahmed Ammar, et al.
Published: (2018-01-01) -
A comparative study between effect of combined intravenous and nebulized amikacin versus intravenous amikacin alone in mechanically ventilated patients with ventilator-associated pneumonia (VAP)
by: Dalia M. El Fawy, et al.
Published: (2020-10-01) -
Treatment of Ventilator-Associated Gram-Negative Pneumonia with Imipenem-Cilastatin/Amikacin Versus Ticarcillin-Clavulanate/Amikacin
by: Ahmet ELALDI, et al.
Published: (2006-06-01) -
Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections
by: Aina Gomila, et al.
Published: (2018-09-01)